ECSP11011200A - Derivados de oxadiazale como agonista de los receptores s1p1 - Google Patents
Derivados de oxadiazale como agonista de los receptores s1p1Info
- Publication number
- ECSP11011200A ECSP11011200A EC2011011200A ECSP11011200A ECSP11011200A EC SP11011200 A ECSP11011200 A EC SP11011200A EC 2011011200 A EC2011011200 A EC 2011011200A EC SP11011200 A ECSP11011200 A EC SP11011200A EC SP11011200 A ECSP11011200 A EC SP11011200A
- Authority
- EC
- Ecuador
- Prior art keywords
- groups
- group
- atoms
- alkyl
- nrarb
- Prior art date
Links
- 102100025750 Sphingosine 1-phosphate receptor 1 Human genes 0.000 title 1
- 101710155454 Sphingosine 1-phosphate receptor 1 Proteins 0.000 title 1
- 239000000556 agonist Substances 0.000 title 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 8
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 7
- 229910003827 NRaRb Inorganic materials 0.000 abstract 5
- 125000004181 carboxyalkyl group Chemical group 0.000 abstract 4
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 abstract 3
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 3
- 125000002853 C1-C4 hydroxyalkyl group Chemical group 0.000 abstract 3
- 125000004429 atom Chemical group 0.000 abstract 3
- 125000005843 halogen group Chemical group 0.000 abstract 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 2
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 abstract 2
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 2
- 125000006645 (C3-C4) cycloalkyl group Chemical group 0.000 abstract 1
- 125000006661 (C4-C6) heterocyclic group Chemical group 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 150000001204 N-oxides Chemical class 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000002837 carbocyclic group Chemical group 0.000 abstract 1
- MPVDXIMFBOLMNW-UHFFFAOYSA-N chembl1615565 Chemical compound OC1=CC=C2C=C(S(O)(=O)=O)C=C(S(O)(=O)=O)C2=C1N=NC1=CC=CC=C1 MPVDXIMFBOLMNW-UHFFFAOYSA-N 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Transplantation (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
Nuevos compuestos que tienen la estructura química representada por la fórmula (I) o sales o N-óxidos de los mismos farmacéuticamente aceptables,Fórmula (I)en los que,A se selecciona del grupo que consiste en -N-, -O- y -S-;B y C se seleccionan independientemente del grupo que consiste en -N- y -O-, con la condición de que al menos dos de A, B y C sean átomos de nitrógeno;G1 se selecciona del grupo que consiste en átomos de hidrógeno y grupos -CRc-, donde Rc representa un átomo de hidrógeno, un átomo de halógeno, un grupo alquilo C1-4 o un grupo alcoxi C1-4;R1 se selecciona del grupo que consiste en átomos de hidrógeno, grupos alquilo C1-4, grupos alcoxi C1-4, grupos cicloalquilo C3-4, y grupos -NRdRe donde Rd y Re se seleccionan independientemente de átomos de hidrógeno y grupos alquilo C1-4;R2 y R3 se seleccionan independientemente del grupo que consiste en átomos de hidrógeno y grupos alquilo C1-4;R4, R5 y R7 se seleccionan independientemente del grupo que consiste en átomos de hidrógeno, átomos de halógeno, grupos alquilo C1-4, grupos alcoxi C1-4 y grupos haloalquilo C1-4;R6 representa un grupo alquilo C1-4 o un grupo hidroxialquilo C1-4; o R6 se selecciona del grupo que consiste en grupos -S(O)2-NRaRb, grupos -(CRfRg)n-(CRhRi)X-(CRjRk)y-NRaRb, grupos -(CH2)n-NRaRb, grupos -O-(CH2)n-NRaRb, grupos -(CH2)n-COOH, grupos -(CH2)n-NRa-CO-Rb', grupos -(CH2)n-NRa-(CH2)p-(NH)q-SO-CH3 y grupos -(CH2)n-CO-NRaRb, en donde n, p, x e y, cada uno independientemente, son números enteros de 0 a 3, q es 0 o 1, Rf, Rg, Rh, Ri, Rj y Rk independientemente representan átomos de hidrógeno o átomos de halógeno,Rb' se selecciona del grupo que consiste en grupos metilsulfonilo, grupos alquilo C1-4, grupos hidroxialquilo C1-4, grupos carboxialquilo C1-4, y grupos haloalquilo C1-4;Ra y Rb se seleccionan independientemente del grupo que consiste en átomos de hidrógeno, grupos metilsulfonilo, grupos alquilo C1-4, grupos hidroxialquilo C1-4, grupos carboxialquilo C1-4, y grupos haloalquilo C1-4, oRa y Rb junto con el átomo de nitrógeno al que están unidos forman un grupo heterocíclico saturado, de 4 a 6 miembros que contiene, como heteroátomos, uno o dos átomos de nitrógeno y que está sustituido con un grupo carboxilo o un grupo carboxialquilo C1-4; oRc junto con R6 forman un anillo carbocíclico C5-8 opcionalmente sustituido con -NHR' en donde R' representa un átomo de hidrógeno o un grupo carboxialquilo C1-4.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09382004A EP2210890A1 (en) | 2009-01-19 | 2009-01-19 | Oxadiazole derivatives as S1P1 receptor agonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP11011200A true ECSP11011200A (es) | 2011-08-31 |
Family
ID=40568602
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EC2011011200A ECSP11011200A (es) | 2009-01-19 | 2011-07-13 | Derivados de oxadiazale como agonista de los receptores s1p1 |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20110274657A1 (es) |
| EP (2) | EP2210890A1 (es) |
| JP (1) | JP2012515182A (es) |
| KR (1) | KR20110110198A (es) |
| CN (1) | CN102282144A (es) |
| AR (1) | AR075022A1 (es) |
| AU (1) | AU2010205825A1 (es) |
| BR (1) | BRPI1005153A2 (es) |
| CA (1) | CA2748394A1 (es) |
| EA (1) | EA201101089A1 (es) |
| EC (1) | ECSP11011200A (es) |
| IL (1) | IL213630A0 (es) |
| MX (1) | MX2011007455A (es) |
| SG (1) | SG172452A1 (es) |
| TW (1) | TW201028407A (es) |
| UY (1) | UY32364A (es) |
| WO (1) | WO2010081692A1 (es) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE028588T2 (hu) | 2005-12-13 | 2016-12-28 | Incyte Holdings Corp | Heteroaril-szubsztituált pirrolo[2,3-b]piridinek és pirrolo[2,3-b]pirimidinek mint Janus-kináz inhibitorok |
| EP2740731B1 (en) | 2007-06-13 | 2016-03-23 | Incyte Holdings Corporation | Crystalline salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
| BRPI1012108B8 (pt) | 2009-05-22 | 2021-05-25 | Incyte Corp | composto 3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il]octa no- ou heptano-nitrila, sua composição, seus usos e processo para preparar um sal de ácido fosfórico |
| NZ596479A (en) | 2009-05-22 | 2014-01-31 | Incyte Corp | N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors |
| US8399451B2 (en) | 2009-08-07 | 2013-03-19 | Bristol-Myers Squibb Company | Heterocyclic compounds |
| TW201113285A (en) | 2009-09-01 | 2011-04-16 | Incyte Corp | Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors |
| CA2792508C (en) | 2010-03-10 | 2018-01-16 | Incyte Corporation | Piperidin-4-yl azetidine derivatives as jak1 inhibitors |
| EA202091303A3 (ru) | 2010-05-21 | 2021-05-31 | Инсайт Холдингс Корпорейшн | Композиция ингибитора jak для местного применения |
| JP2013544811A (ja) * | 2010-11-03 | 2013-12-19 | ブリストル−マイヤーズ スクイブ カンパニー | 自己免疫疾患および血管疾患の治療用のｓ１ｐ１アゴニストとしての複素環式化合物 |
| ES2536415T3 (es) | 2010-11-19 | 2015-05-25 | Incyte Corporation | Pirrolopiridinas y pirrolopirimidinas sustituidas heterocíclicas como inhibidores de JAK |
| CA2818542A1 (en) | 2010-11-19 | 2012-05-24 | Incyte Corporation | Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors |
| EP2455080A1 (en) * | 2010-11-23 | 2012-05-23 | Almirall, S.A. | S1P1 receptor agonists for use in the treatment of multiple sclerosis |
| EP2455081A1 (en) * | 2010-11-23 | 2012-05-23 | Almirall, S.A. | S1P1 receptor agonists for use in the treatment of crohn's disease |
| WO2012112847A1 (en) | 2011-02-18 | 2012-08-23 | Novartis Pharma Ag | mTOR/JAK INHIBITOR COMBINATION THERAPY |
| US8691807B2 (en) | 2011-06-20 | 2014-04-08 | Incyte Corporation | Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors |
| WO2013023119A1 (en) | 2011-08-10 | 2013-02-14 | Novartis Pharma Ag | JAK P13K/mTOR COMBINATION THERAPY |
| TW201313721A (zh) | 2011-08-18 | 2013-04-01 | Incyte Corp | 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物 |
| UA111854C2 (uk) | 2011-09-07 | 2016-06-24 | Інсайт Холдінгс Корпорейшн | Способи і проміжні сполуки для отримання інгібіторів jak |
| WO2013113776A1 (en) | 2012-02-03 | 2013-08-08 | Basf Se | Fungicidal pyrimidine compounds |
| WO2013113720A1 (en) | 2012-02-03 | 2013-08-08 | Basf Se | Fungicidal pyrimidine compounds |
| WO2013113791A1 (en) | 2012-02-03 | 2013-08-08 | Basf Se | Fungicidal pyrimidine compounds |
| IN2014DN07224A (es) | 2012-02-03 | 2015-04-24 | Basf Se | |
| CA2862354A1 (en) | 2012-02-03 | 2013-08-08 | Basf Se | Fungicidal pyrimidine compounds |
| WO2013113773A1 (en) | 2012-02-03 | 2013-08-08 | Basf Se | Fungicidal pyrimidine compounds |
| WO2013113716A1 (en) | 2012-02-03 | 2013-08-08 | Basf Se | Fungicidal pyrimidine compounds |
| TW201406761A (zh) | 2012-05-18 | 2014-02-16 | Incyte Corp | 做爲ｊａｋ抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物 |
| KR102242077B1 (ko) | 2012-11-15 | 2021-04-20 | 인사이트 홀딩스 코포레이션 | 룩솔리티니브의 서방성 제형 |
| TWI613182B (zh) | 2013-02-21 | 2018-02-01 | 必治妥美雅史谷比公司 | 雙環化合物 |
| EP3489239B1 (en) | 2013-03-06 | 2021-09-15 | Incyte Holdings Corporation | Processes and intermediates for making a jak inhibitor |
| MX376856B (es) | 2013-08-07 | 2025-03-07 | Incyte Holdings Corp | Formas de dosificacion de liberacion prolongada para un inhibidor de jak 1 (cinasa de janus 1). |
| WO2015184305A1 (en) | 2014-05-30 | 2015-12-03 | Incyte Corporation | TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1 |
| UY36274A (es) | 2014-08-20 | 2016-02-29 | Bristol Myers Squibb Company Una Corporación Del Estado De Delaware | Compuestos bicíclicos sustituidos como agonistas selectivos de la actividad del receptor s1p1 acoplado a la proteína g |
| MA41139B1 (fr) | 2014-12-11 | 2026-02-27 | Laboratoires Juvise Pharmaceuticals | Combinaison pharmaceutique comprenant du ponesimod et son utilisation dans le traitement de la sclérose en plaque |
| HUE057865T2 (hu) | 2014-12-11 | 2022-06-28 | Actelion Pharmaceuticals Ltd | A poneszimodra, egy szelektív S1P1 receptor agonistára vonatkozó adagolási rend |
| RU2754845C2 (ru) * | 2016-07-22 | 2021-09-08 | Медшайн Дискавери Инк. | Агонист s1p1 и его применение |
| TW201924683A (zh) | 2017-12-08 | 2019-07-01 | 美商英塞特公司 | 用於治療骨髓增生性贅瘤的低劑量組合療法 |
| MD3746429T2 (ro) | 2018-01-30 | 2022-08-31 | Incyte Corp | Procedee pentru prepararea de (1-(3-fluoro-2-(trifluorometil)izonicotinil)piperidin-4-onă) |
| KR20260080448A (ko) | 2018-03-30 | 2026-06-02 | 인사이트 코포레이션 | Jak 억제제를 사용하는 화농성 한선염의 치료 |
| MX2022005766A (es) | 2019-11-19 | 2022-08-08 | Trevena Inc | Compuestos y métodos para la preparación de compuestos moduladores de esfingosina 1-fosfato tipo 1 (s1p1). |
| US11833155B2 (en) | 2020-06-03 | 2023-12-05 | Incyte Corporation | Combination therapy for treatment of myeloproliferative neoplasms |
| ES3074322T3 (en) * | 2021-02-10 | 2026-07-20 | Icahn School Med Mount Sinai | Oxadiazolyl dihydropyrano[2,3-b]pyridine inhibitors of hipk2 for treating kidney fibrosis |
| CA3264196A1 (en) * | 2022-08-05 | 2024-02-08 | Icahn School Of Medicine At Mount Sinai | HETEROCYCLIC COMPOUND CONTAINING OXYGEN AND ITS USE |
| IL328566A (en) | 2023-12-22 | 2026-07-01 | Suven Life Sciences Ltd | Organic compounds as positive allosteric modulators of the M4 muscarinic receptor (M4 PAMS) |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2303792A (en) | 1992-06-23 | 1994-01-24 | Motorola, Inc. | Multi-modulation scheme compatible radio |
| PL182198B1 (en) | 1995-06-21 | 2001-11-30 | Asta Medica Ag | Pharmaceutic powder holding container with integrated measuring device and powdered |
| DE10129703A1 (de) | 2001-06-22 | 2003-01-02 | Sofotec Gmbh & Co Kg | Zerstäubungssystem für eine Pulvermischung und Verfahren für Trockenpulverinhalatoren |
| DE10202940A1 (de) | 2002-01-24 | 2003-07-31 | Sofotec Gmbh & Co Kg | Patrone für einen Pulverinhalator |
| JP5227492B2 (ja) | 2002-05-16 | 2013-07-03 | ノバルティス アーゲー | 癌におけるｅｄｇレセプター結合剤の使用 |
| GB0217152D0 (en) | 2002-07-24 | 2002-09-04 | Novartis Ag | Organic compounds |
| CA2524867A1 (en) * | 2003-05-15 | 2004-12-02 | Merck & Co., Inc. | 3-(2-amino-1-azacyclyl)-5-aryl-1,2,4-oxadiazoles as s1p receptor agonists |
| EP1484057A1 (en) | 2003-06-06 | 2004-12-08 | Aventis Pharma Deutschland GmbH | Use of 2-amino-1-3-propanediol derivatives for the manufacture of a medicament for the treatment of various types of pain |
| WO2005025553A2 (en) | 2003-09-12 | 2005-03-24 | Neuronova Ab | Treatment of disorders of nervous systemsystem with fty720 |
| WO2005032465A2 (en) * | 2003-10-01 | 2005-04-14 | Merck & Co., Inc. | 3,5-aryl, heteroaryl or cycloalkyl substituted-1,2,4-oxadiazoles as s1p receptor agonists |
| US7605171B2 (en) * | 2003-12-17 | 2009-10-20 | Merck & Co., Inc. | (3,4-disubstituted)propanoic carboxylates as S1P (Edg) receptor agonists |
| GB0329498D0 (en) | 2003-12-19 | 2004-01-28 | Novartis Ag | Organic compounds |
| US20080306124A1 (en) * | 2005-06-08 | 2008-12-11 | Rainer Albert | Polycyclic Oxadiazoles or I Soxazoles and Their Use as Sip Receptor Ligands |
| KR20080086546A (ko) | 2006-01-27 | 2008-09-25 | 유니버시티 오브 버지니아 페이턴트 파운데이션 | 신경병증성 통증의 치료 방법 |
| GB0601744D0 (en) * | 2006-01-27 | 2006-03-08 | Novartis Ag | Organic compounds |
| TWI389683B (zh) | 2006-02-06 | 2013-03-21 | Kyorin Seiyaku Kk | A therapeutic agent for an inflammatory bowel disease or an inflammatory bowel disease treatment using a 2-amino-1,3-propanediol derivative as an active ingredient |
| ES2414205T3 (es) | 2006-06-02 | 2013-07-18 | The Ohio State University Research Foundation | Agentes terapéuticos para el tratamiento de linfoma de células del manto |
| GB0612721D0 (en) | 2006-06-27 | 2006-08-09 | Novartis Ag | Organic compounds |
| BRPI0715950A2 (pt) | 2006-08-17 | 2013-07-30 | Univ Chicago | tratamento de doenÇas inflamatàrias |
-
2009
- 2009-01-19 EP EP09382004A patent/EP2210890A1/en not_active Withdrawn
- 2009-12-23 UY UY0001032364A patent/UY32364A/es not_active Application Discontinuation
-
2010
- 2010-01-13 TW TW099100840A patent/TW201028407A/zh unknown
- 2010-01-14 CA CA2748394A patent/CA2748394A1/en not_active Abandoned
- 2010-01-14 EA EA201101089A patent/EA201101089A1/ru unknown
- 2010-01-14 AU AU2010205825A patent/AU2010205825A1/en not_active Abandoned
- 2010-01-14 KR KR1020117016785A patent/KR20110110198A/ko not_active Withdrawn
- 2010-01-14 WO PCT/EP2010/000158 patent/WO2010081692A1/en not_active Ceased
- 2010-01-14 EP EP10700383A patent/EP2387571A1/en not_active Withdrawn
- 2010-01-14 BR BRPI1005153A patent/BRPI1005153A2/pt not_active IP Right Cessation
- 2010-01-14 US US13/144,377 patent/US20110274657A1/en not_active Abandoned
- 2010-01-14 MX MX2011007455A patent/MX2011007455A/es not_active Application Discontinuation
- 2010-01-14 SG SG2011048329A patent/SG172452A1/en unknown
- 2010-01-14 JP JP2011545678A patent/JP2012515182A/ja active Pending
- 2010-01-14 CN CN2010800049696A patent/CN102282144A/zh active Pending
- 2010-01-15 AR ARP100100089A patent/AR075022A1/es unknown
-
2011
- 2011-06-16 IL IL213630A patent/IL213630A0/en unknown
- 2011-07-13 EC EC2011011200A patent/ECSP11011200A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2011007455A (es) | 2011-08-03 |
| BRPI1005153A2 (pt) | 2019-09-24 |
| WO2010081692A1 (en) | 2010-07-22 |
| TW201028407A (en) | 2010-08-01 |
| US20110274657A1 (en) | 2011-11-10 |
| JP2012515182A (ja) | 2012-07-05 |
| AR075022A1 (es) | 2011-03-02 |
| IL213630A0 (en) | 2011-07-31 |
| UY32364A (es) | 2010-02-26 |
| EA201101089A1 (ru) | 2012-02-28 |
| SG172452A1 (en) | 2011-07-28 |
| KR20110110198A (ko) | 2011-10-06 |
| CA2748394A1 (en) | 2010-07-22 |
| AU2010205825A1 (en) | 2011-07-07 |
| EP2210890A1 (en) | 2010-07-28 |
| CN102282144A (zh) | 2011-12-14 |
| EP2387571A1 (en) | 2011-11-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR075022A1 (es) | Derivados oxadiazole como agonistas de los receptores de esfingosina-1-fosfato (s1p1) | |
| ECSP11011083A (es) | Nuevos compuestos | |
| ES2521596T3 (es) | Combinación del compuesto GlyT1 con antipsicóticos | |
| AR081387A1 (es) | Derivados de ciclohexilamina que tienen actividad como agonistas adrenergicos beta 2 y como antagonistas muscarinicos m3, composiciones farmaceuticas y uso de los mismos. | |
| AR079164A1 (es) | Derivados heterociclicos de indol, composiciones farmaceuticas que los comprenden y uso de los mismos para la profilaxis o tratamiento de enfermedades alergicas, inflamatorias y/o autoinmunes. | |
| AR095609A1 (es) | Compuestos de pirrolopiridina | |
| AR099367A1 (es) | Inhibidores de la tirosina quinasa de bruton | |
| PE20221027A1 (es) | Nuevos inhibidores de braf como rompedores de la paradoja | |
| ES2684517T3 (es) | Compuestos de heterociclilo como inhibidores de MEK | |
| AR108356A1 (es) | Derivados aromáticos de sulfonamida | |
| AR081859A1 (es) | Pirimidinas 2,4,6-trisustituidas, composiciones farmaceuticas que las comprenden y su uso en el tratamiento de tumores sensibles a la inhibicion de la cinasa atr | |
| ECSP13012771A (es) | Compuestos heterocíclicos nitrogenados sustituidos fusionados en posición 6,6 y usos de los mismos | |
| AR067646A1 (es) | Ariloxazoles sustituidos y su uso | |
| ES2570756T3 (es) | Derivados pirimidinilpirrolopiridinona sustituidos, proceso para su preparación y su uso como inhibidores de cinasa | |
| ES2746839T3 (es) | Derivados de pirimidina y triazina y su uso como inhibidores de AXL | |
| AR064416A1 (es) | Derivados de purina, piridina y pirimidina condensadas con heterociclos, moduladores de pka y/o pkb, composiciones farmaceuticas que los contienen, y usos para el tratamiento de enfermedades hiperproliferativas. | |
| AR081331A1 (es) | Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos | |
| BR112015015275A8 (pt) | composto heterocíclico substituído por halogênio, antagonista do receptor de lpa, composição farmacêutica e uso | |
| AR072016A1 (es) | Derivados de isoxazol que funcionan como potenciadores de los receptores de glutamato | |
| AR076900A1 (es) | Derivados heterociclicos nitrogenados utiles como agentes antivirales, composiciones farmaceuticas que los contienen y uso de los mismos como inhibidores del vhc | |
| AR086983A1 (es) | Derivados de azetidinil fenil, piridil o pirazinil carboxamida como inhibidores de jak | |
| AR058769A1 (es) | Inhibidores de peptidil-deformilasa(pdf),utiles para el tratamiento de la tuberculosis y composiciones farmaceuticas que los contienen. | |
| AR088828A1 (es) | DERIVADOS DE CICLOHEXILAMINA QUE TIENEN ACTIVIDAD COMO AGONISTAS ADRENERGICOS b2 Y COMO ANTAGONISTAS MUSCARINICOS M3 | |
| AR089143A1 (es) | Triazolopiridinas sustituidas con actividad inhibidora de ttk | |
| PE20160201A1 (es) | Bencil-1h-pirazol[3,4-b]piridinas y su uso |